Q-omics provides the consensus-scored PITRM1 profile across patient tissues and cancer cell-line models. PITRM1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, PITRM1 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, PITRM1 RNA expression shows 19,037 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight CESC, COAD, and ACC as cancer lineages where PITRM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PITRM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PITRM1 survival associations across molecular data types. PITRM1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PITRM1 RNA expression–survival associations across cancer types. High PITRM1 expression shows unfavorable associations in CESC, ACC, BLCA, BRCA, SKCM and UVM. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for PITRM1 RNA expression.
This table summarizes PITRM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PITRM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PITRM1 shows lower tumor expression in THCA and higher tumor expression in COAD, LUAD, HNSC, KIRP and KIRC. The COAD box plot shows higher PITRM1 RNA expression in tumor versus normal tissue (log2 FC = +0.660, t-test p < 0.001).
This table shows molecular features associated with PITRM1 in patient tissues and cancer cell lines. In patient samples, PITRM1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PITRM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
